Diagnostic strategies and the incidence of prostate cancer: Reasons for the low reported incidence of prostate cancer in China

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 9-13

  Zhang, Ling ^a   Wu, Shan ^b   Guo, Li Rong ^a   Zhao, Xue Jian ^a  

^a JILIN UNIVERSITY   (China)

^b Basic Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CHINA; DIGITAL RECTAL EXAMINATION; HUMAN; MASS SCREENING; NORTH AMERICA; PREVALENCE; PROSTATE CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; AGED; BLOOD; ETHNOLOGY; HEALTH; INCIDENCE; MALE; MIDDLE AGED; PROSTATE TUMOR; UNITED STATES;

AGED; AGED, 80 AND OVER; CHINA; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WORLD HEALTH;

EID: 69449093417     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.21     Document Type: Review

References (30)

1. Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda MD. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
2. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: An ecological study. Lancet Oncol 2008; 9: 445-52.
3. Ferlay J, Bocani GLO. Cancer Incidence and Mortality Worldwide. Lyon: IARC Press; 1998.
4. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer-Base No 5, version 2.0. Lyon: IARC Press; 2004.
5. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007; 57: 190-205.
6. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
7. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20-37.
8. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42-6.
9. Ye DW, Li CL. Epidemiological trends of prostate cancer: Retrospect and prospect. China Oncol 2007; 17: 177-80.
10. Gu FL, Liu YL. Changing status of genitourinary cancer in recent 50 years. Chin J Urol 2002; 23: 88-90.
11. Zhang L, Ji GY, Li XM, Li SW, Gao HW, et al. The influence of mass screening for prostate cancer on the diagnostic status of the clinical prostate cancer. Chin J Urol 2004; 25: 103-4.
12. Li XM, Tsuji I, Kuwahara M, Zhang HF, Wang HL, et al. Mass screening of prostate cancer in Changchun City of China. Int Urol Nephrol 2004; 36: 541-8.
13. Kuwahara M, Tochigi T, Kawamura S, Ogata Y, Xu N, et al. Mass screening for prostate cancer: A comparative study in Natori, Japan and Changchun, China. Urology 2003; 61: 137-41.
14. Zhang HF, Wang HL, Xu N, Li SW, Ji GY, et al. Mass screening of 12 027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J (Engl) 2004; 117: 67-70.
15. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
16. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83.
17. Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996; 77: 150-9.
18. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10-30.
19. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, et al. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004; 172: 1297-301.
20. Ji GY, Zhang L, Zhao W, Gao HW, Kong XB, et al. Transrectal ultrasound-directed prostate biopsy can detect early prostate cancer. Chin J Androl 2005; 19: 22-4, 33.
21. Gao HW, Li YL, Wu S, Wang YS, Zhang HF, et al. Mass screening of prostate cancer in a Chinese population: The relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005; 7: 159-63.
22. Li Y, Mao JH, Zhang L, Ji GY, Pan YZ, et al. Study on relationship between the expression of PSA mRNA and protein in the mononuclear cells of the peripheral blood and prostate cancer micrometastasis. Chin J Androl 2006; 20: 5-7.
23. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, et al. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase- PCR. Clin Cancer Res 2007; 13: 1192-7.
24. Pan YZ, Xiao XY, Zhao D, Zhang L, Ji GY, et al. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. Asian J Androl 2006; 8: 45-51.
25. Li XM, Zhang L, Li J, Li Y, Wang HL, et al. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL. Asian J Androl 2005; 7: 323-8.
26. Zhang L, Ji GY, Zhang XY, Li XM, Wang WH, et al. Estimation of prostate cancer early diagnosis using free/total PSA ratio with a population-based screening data. J US-China Med Sci 2005; 1: 29-33.
27. Stephan C, Cammann H, Meyer HA, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 2007; 249: 18-29.
28. Pelzer AE, Volgger H, Bektic J, Berger AP, Rehder P, et al. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU Int 2005; 96: 995-8.
29. Gregorio EP, Grando JP, Saqueti EE, Almeida SH, Moreira HA, et al. Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/mL. Int Braz J Urol 2007; 33: 151-60.
30. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008; 71: 1016-9.